This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Reports for PayPal, Netflix & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings, Inc. (PYPL), Netflix, Inc. (NFLX), and Sanofi (SNY).
Pharma Stock Roundup: FDA Nod for SNY's Pompe Drug & New Use of MRK's Keytruda
by Kinjel Shah
FDA approves Sanofi's (SNY) Nexviazyme for late-onset Pompe disease and Merck's (MRK) Keytruda plus Lenvima for first-line kidney cancer.
Biotech Stock Roundup: REGN Q2 Earnings Beat, BLUE, BYSI's Updates & More
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Regeneron (REGN) and regulatory update from bluebird (BLUE) among others.
Sanofi (SNY) Pompe Disease Drug Receives FDA's Approval
by Zacks Equity Research
The FDA gives approval to Sanofi's (SNY) Nexviazyme (avalglucosidase alfa) for treating late-onset Pompe disease.
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, SNY's TBIO Buyout, FDA Updates
by Kinjel Shah
Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce Q2 results. FDA approves AstraZeneca's (AZN) lupus medicine, Saphnelo. Sanofi (SNY) to buy Translate Bio.
Novo Nordisk's (NVO) Q2 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) delivers better-than-expected results for Q2. Sales are aided by growth in Diabetes and Obesity Care owing to elevated GLP-1 revenues.
Regeneron (REGN) Q2 Earnings Beat, REGEN-COV Boosts Performance
by Zacks Equity Research
Regeneron (REGN) beats on Q2 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and significant contribution from REGEN-COV.
Alnylam's (ALNY) Q2 Earnings Miss Estimates, 2021 Guidance Up
by Zacks Equity Research
Alnylam (ALNY) misses Q2 estimates for earnings but beats the same for sales. The company raises revenue guidance for 2021.
Global Blood's (GBT) Q2 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a narrower-than-expected loss in the second quarter of 2021 while its revenues also beat estimates.
Delta Variant Surge Brings Biotech ETFs in Focus
by Sweta Jaiswal, FRM
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2021 results.
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV
by Kinjel Shah
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance
by Zacks Equity Research
BioMarin (BMRN) beats on both earnings and revenues in the second quarter of 2021.
Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised
by Zacks Equity Research
Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.
This is Why Sanofi (SNY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Top Research Reports for Berkshire Hathaway, PayPal & Procter & Gamble
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), PayPal (PYPL), and Procter & Gamble (PG).
Is Sanofi (SNY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Sanofi (SNY) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
SNY vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara
by Zacks Equity Research
The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.
3 Reasons to Invest in Regeneron Pharmaceuticals (REGN) Now
by Zacks Equity Research
Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.
Pharma Stock Roundup: EU Nod to RHHBY, MRK Drugs, FDA and Pipeline Updates
by Kinjel Shah
EU approves Roche's (RHHBY) Enspryng and Merck's (MRK) Keytruda for a new indication. FDA grants EUA to Roche's Actemra for COVID-19.
Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.